New PRI Brief: Washington Must End Physician Price Controls, Reform Medicare Payment System to Prevent Doctor Shortages
SACRAMENTO, Calif., July 25, 2024 /PRNewswire/ -- A new brief released today by the Center for Medical Economics and Innovation at the nonpartisan Pacific Research Institute finds that artificially low reimbursement rates used by Medicare to contain costs are threatening patient care, and reform is needed to prevent future doctor shortages.
"Price controls used by government-run health care systems globally to contain costs lead to delays, lower quality, and worse health outcomes," said Dr. Wayne Winegarden, director of PRI's Center for Medical Economics and Innovation. "U.S. patients could also face doctor shortages unless Medicare's low doctor reimbursement rates are reformed and proposals for single-payer health care are rejected."
Doctor shortages are a common experience in government-run health care systems globally. According to a 2022 Our Care survey, 22% of Canadians do not have a family doctor or nurse practitioner, while the average number of doctors per 1,000 people in the United Kingdom was just 2.9 per 1,000 people, compared to 3.7 per 1,000 people in OECD European Union nations.
A growing driver of doctor shortages in the U.S. and around the world is inadequate doctor compensation, which arises because government-run health care systems such as Medicare impose increasingly uneconomical price controls on doctors to control rising costs. The problem would grow worse in the U.S. if a single-payer health care system is enacted.
Medicare's low reimbursement rates bring real income losses for physicians as the fear of doctor shortages is growing. According to the brief:
While average prices grew 27.4% from 2013 through 2022, reimbursement rates grew just 7.3% percent based on the average Medicare payment amount and 1.3% based on the average Medicare standardized payment amount (adjusting payments for geographic differences in payment rates).
Between 2001 and 2024, consumer (78.4%), producer (83.7%), and health care (110.3%) prices grew more than double the increases in physician office prices (32.5%), documenting the income losses for doctors.
Since 2020, physician office price increases (6.6%) continued to lag the growth in consumer (22.3%) and producer (38.7%) prices, though health care price increases slowed significantly (8.7%).
Unless the problem of low reimbursement rates is resolved, patients will have less access to care and increased wait times to see a doctor or specialist, while overall health care costs would ironically increase. Vulnerable and rural populations would be impacted the most.
Among the reforms suggested in the brief are:
Indexing physician reimbursement rates to a cost index, such as the Medicare Economic Index, to prevent inflation from eroding physician incomes.
Reforming the Merit-based Incentive Payment System (MIPS) program, which addresses problems associated with the doctor fee-for-service model and incentivizes value-based care, to reduce the costly burdens on providers and incentivize more innovative, patient-driven care.
The Pacific Research Institute (www.pacificresearch.org) champions freedom, opportunity, and personal responsibility through free-market policy ideas. Follow PRI on Facebook,Twitter, and LinkedIn.
Edesa Biotech, Inc. , a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases, today reported financial results for the fiscal year ended September 30, 2024 and provided an update...
K-Bro Linen Inc. (the "Corporation") announced today a dividend of 10.00 cents CDN per common share of the Corporation for the period from December 1 to 31, 2024, to be paid on January 15, 2025 to holders of record of common shares on December 31,...
Scholar Rock , a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy, cardiometabolic disorders, and other serious diseases where protein growth factors play a fundamental role, today announced...
Summit Therapeutics Inc. ("Summit," "we," or the "Company") today announced the grant of inducement awards of options to purchase a collective total of up to 98,000 shares of common stock. Awards were made to six new employees of the Company. The...
Kyverna Therapeutics, Inc. (Kyverna), a clinical-stage biopharmaceutical company focused on developing cell therapies for patients with autoimmune diseases, announced the recent appointments of Dan Maziasz as Chief Business Officer, Cara Bauer as...
netWelltm, a leading healthcare sharing ministry based in Austin, Texas, is thrilled to announce the expansion of its services to offer members more personalized, accessible, and affordable healthsharing solutions.
"These expanded services bring a...